Alto Neuroscience, Inc.

ANRO

US02157Q1094

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-05-21 pm EDT			5-day change	1st Jan Change
12.69 ^USD	+2.34%		-10.38%	0.00%

May. 14	Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia	CI

Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P TMI Index

March 17, 2024

Latest news about Alto Neuroscience, Inc.

Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia	Apr. 23	CI
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients	Apr. 03	MT
Alto Neuroscience, Inc. Announces Initiation of Phase 2 Study of Alto-203 in Patients with Major Depressive Disorder	Apr. 03	CI
Alto Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P TMI Index	Mar. 17	CI
Alto Neuroscience Appoints Maha Radhakrishnan to Board of Directors	Mar. 11	CI
Stifel Initiates Alto Neuroscience With Buy Rating, Price Target is $32	Feb. 27	MT
Baird Initiates Alto Neuroscience With Outperform Rating, Price Target is $32	Feb. 27	MT
Jefferies Initiates Alto Neuroscience With Buy Rating, Price Target is $33	Feb. 27	MT
Alto Neuroscience Insider Bought Shares Worth $272,000, According to a Recent SEC Filing	Feb. 07	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Feb. 02	MT
Sector Update: Health Care Stocks Decline Friday Afternoon	Feb. 02	MT
Alto Neuroscience's Shares Surge in Market Debut	Feb. 02	MT
Alto Neuroscience Prices Upsized Initial Public Offering	Feb. 02	MT
Alto Neuroscience, Inc. has completed an IPO in the amount of $128.64 million.	Feb. 01	CI

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individualsâ neurobiology to develop personalized and effective treatment options. Through insights derived from the Companyâs scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.4 USD

Average target price

33.69 USD

Spread / Average Target

+171.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALTO NEUROSCIENCE, INC.	0.00%	333M
MODERNA, INC.	+44.48%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-0.86%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	19B
BIO-TECHNE CORPORATION	+7.15%	13B
MEDPACE HOLDINGS, INC.	+29.40%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.19B

Other Biotechnology & Medical Research